Psoriasis RCT studied ADA+MTX (31) vs ADA (30); after 12 mos, a (non-significant) better drug survival w/ ADA-MTX (74 vs 59%; p=0.15). Also favoring, but not signif was PASI 75 (58 vs 37%). Fewer anti-ADA Abs seen w/ ADA-MTX (23 vs 60%; p<0.01) https://t.co/9CAQrpl6hU https://t.co/mr0ZaJ9mbW